肝细胞癌
二甲双胍
医学
癌
糖尿病
2型糖尿病
药品
内科学
肿瘤科
癌症
临床试验
药理学
内分泌学
作者
Kaizhen Wang,Kuojun Zhang,Xiangyu Zhang,Dong Chen,Sheng Jiang
出处
期刊:Mini-reviews in Medicinal Chemistry
[Bentham Science]
日期:2023-06-01
卷期号:23 (11): 1154-1166
被引量:1
标识
DOI:10.2174/1389557522666220623150717
摘要
Abstract: Metformin is an oral hypoglycemic drug, the first option used to treat type 2 diabetes mellitus due to its high efficacy and low cost. Recently, it has drawn attention among researchers due to its new-found antitumor effect. Growing evidence showed that metformin could inhibit cancer progression, especially in hepatocellular carcinoma, and several clinical trials are underway. However, the underlying mechanisms of the inhibition of hepatocellular carcinoma remain to be further explored and clarified. Herein, we reviewed the latest findings of how metformin acts against hepatocellular carcinoma and the proposed mechanisms. In addition, we included related preclinical trials, along with the limitations and perspectives of its treatment in hepatocellular carcinoma, providing novel ideas for research to conquer hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI